Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
268 Citations•2020•
William J. Sandborn, Subrata Ghosh, Julián Panés
In a phase 2b trial, 8 weeks treatment with upadacitinib was more effective than placebo for inducing remission in patients with moderately to severely active UC.
Abstract
In a phase 2b trial, 8 weeks of treatment with upadacitinib was more effective than placebo for inducing remission in patients with moderately to severely active UC. (ClinicalTrials.gov, Number: NCT02819635).